IMNM

Based on Immunome, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Immunome do?

Immunome is a clinical-stage biopharmaceutical company that discovers and develops antibody therapeutics. Its pipeline targets oncology — specifically a tumor-derived immune checkpoint — and infectious disease, including a COVID-19 antibody cocktail program. The company has not yet commercialized any products.

Does IMNM pay dividends?

No, Immunome does not pay a dividend. Clinical-stage biotechs typically reinvest all available capital into research and development. Investors in IMNM are generally focused on pipeline value rather than income generation.

When does IMNM report earnings?

Immunome reports on a quarterly cadence typical of US-listed companies. Because it is pre-revenue, reports center on cash position and pipeline updates rather than traditional earnings metrics. Check Immunome's investor relations page for the most current schedule.

Is IMNM a good stock to buy?

UQS Score rates IMNM as Poor overall, driven by Weak Quality and Moat pillars alongside an Elevated Valuation. The Growth pillar offers relative optimism tied to pipeline potential. Whether IMNM fits a portfolio depends on individual risk tolerance and conviction in the clinical programs. View the full pillar breakdown on UQS Pro.

Is IMNM overvalued?

The UQS Valuation pillar for IMNM is rated Elevated, suggesting the current market price reflects optimistic assumptions about future clinical success. For a pre-revenue company, valuation is inherently tied to pipeline probability rather than current financials.

How does IMNM compare to its competitors?

Compared to peers like Syndax Pharmaceuticals, Ocular Therapeutix, and Aurinia Pharmaceuticals, Immunome is differentiated by its antibody-based immune checkpoint focus in oncology. Aurinia has reached commercial stage, while Immunome and Syndax remain in earlier development phases. UQS Pro shows side-by-side pillar comparisons.

What is IMNM's market cap bracket?

Immunome is classified as a mid-cap company based on its current market capitalization. This places it in a bracket that can attract both institutional and retail investor interest, though clinical-stage mid-caps carry unique volatility characteristics.

Who founded Immunome?

Immunome was incorporated in 2006. Founding and leadership history is publicly available through the company's official filings and investor relations materials for those seeking detailed background on the founding team.

Is IMNM a long-term quality investment?

As a long-term quality indicator, UQS rates IMNM as Poor, reflecting current Weak scores in Quality and Moat. Long-term quality typically requires durable competitive advantages and consistent financial performance — characteristics that clinical-stage companies must still demonstrate. Pipeline success could change this profile over time.

What is the main competitive advantage of Immunome?

Immunome's potential advantage lies in its proprietary antibody discovery approach targeting novel immune checkpoints, particularly the IL-38 pathway in oncology. However, the UQS Moat pillar is currently rated Weak, indicating this advantage has not yet translated into a durable, defensible market position.

What sector does IMNM belong to?

Immunome operates in the Healthcare sector, specifically within the biopharmaceutical and clinical-stage drug development segment. Investors can explore other [Healthcare sector stocks](/sector/healthcare) rated by UQS Score for broader context.

Is IMNM a growth stock or value stock?

Based on UQS pillar labels, IMNM leans toward the growth category — the Growth pillar is rated Good, reflecting pipeline optionality. However, the Elevated Valuation pillar means investors are already paying a premium for that potential, which reduces the margin of safety typically associated with value investing.

Immunome, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.

Immunome, Inc. demonstrates healthy growth trends across revenue and earnings.

Immunome, Inc. has some risk factors including moderate leverage or solvency concerns.

Immunome, Inc. appears expensively valued relative to its fundamentals and growth prospects.

Immunome, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for IMNM.

The UQS (Unified Quality Score) for Immunome, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Immunome, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Immunome, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.